Enlivex Therapeutics Ltd. (ENLV) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Ness Ziona, イスラエル. 現CEOは Oren Hershkovitz.
ENLV を有する IPO日 2014-07-31, 71 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $19.47M.
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
